Bioequivalence between generic tacrolimus products marketed in Spain by adjusted indirect comparison

@article{Herrnz2012BioequivalenceBG,
  title={Bioequivalence between generic tacrolimus products marketed in Spain by adjusted indirect comparison},
  author={Marta Herr{\'a}nz and Susana Morales-Alcelay and Ma Teresa Corredera-Hern{\'a}ndez and Jos{\'e} Mar{\'i}a de la Torre-Alvarado and Antonio Bl{\'a}zquez-P{\'e}rez and Ma Luisa Su{\'a}rez-Gea and Covadonga {\'A}lvarez {\'A}lvarez and Alfredo Garc{\'i}a-Arieta},
  journal={European Journal of Clinical Pharmacology},
  year={2012},
  volume={69},
  pages={1157-1162}
}
The objective of the study was to investigate the relative bioavailability between the generic tacrolimus products that are presently authorized in Spain by adjusted indirect comparison. This was based on demonstration of bioequivalence with the reference product (Prograf, Astellas Pharma), which makes these generic tacrolimus products prescribable, switchable and therapeutically equivalent to the reference product; yet, according to Spanish legislation, only prescribers can switch tacrolimus… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.
12 Citations
17 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 17 references

Design and analysis of bioavailability and bioequivalence studies, 2nd edn

  • SC Chow, JP Liu
  • 2000
Highly Influential
3 Excerpts

Similar Papers

Loading similar papers…